KarXT

Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Reuters
Sun, 04/7/24 - 04:42 pm
Bristol Myers Squibb
schizophrenia
clinical trials
KarXT
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive
Fri, 12/22/23 - 09:44 am
Bristol Myers Squibb
Karuna Therapeutics
schizophrenia
M&A
KarXT
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Pharmaphorum
Wed, 11/29/23 - 11:57 am
Karuna
KarXT
FDA
schizophrenia
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Fierce Biotech
Fri, 11/17/23 - 11:31 am
Karuna Therapeutics
KarXT
blood pressure
schizophrenia
Karuna submits schizophrenia drug for US approval
BioPharma Dive
Thu, 09/28/23 - 12:02 pm
Karuna Therapeutics
KarXT
schizophrenia
FDA
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Thu, 03/23/23 - 11:49 am
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Mon, 03/20/23 - 09:53 am
Karuna
clinical trials
schizophrenia
KarXT
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
Tue, 01/10/23 - 06:37 pm
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Mon, 01/9/23 - 10:31 am
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
BioPharma Dive
Tue, 12/6/22 - 08:45 pm
Karuna Therapeutics
Pharma CEOs
schizophrenia
FDA
KarXT
Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing
Fierce Biotech
Mon, 08/8/22 - 10:14 am
Karuna Therapeutics
clinical trials
schizophrenia
KarXT
Karuna seeks a novel schizophrenia mechanism
EP Vantage
Thu, 06/23/22 - 10:31 am
Karuna Therapeutics
antipsychotics
schizophrenia
KarXT
10 clinical trials to watch in the first half of 2022
BioPharma Dive
Mon, 01/3/22 - 10:46 am
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Biopharma Dive
Tue, 11/26/19 - 11:41 pm
Karuna
schizophrenia
KarXT
Karuna Therapeutics Files for $52 Million Offering
CP Wire
Tue, 11/19/19 - 02:36 pm
Karuna Therapeutics
schizophrenia
KarXT
Karuna Therapeutics Files for $52 Million Offering
Tue, 11/19/19 - 02:35 pm
Karuna Therapeutics
schizophrenia
psychosis
KarXT
Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
Benzinga
Mon, 11/18/19 - 10:19 am
Karuna Therapeutics
schizophrenia
clinical trials
KarXT
Karuna looks past schizophrenia with $68M series B
BioCentury
Mon, 03/18/19 - 10:37 am
Karuna
KarXT
schizophrenia
geriatric psychosis
pain

Pages